|Property||Resources - Mining|
|Resources - Oil & Gas||Technology|
|EQS Group||Grand City Properties|
|Game Digital||Arix Bioscience|
|Scherzer & Co||Mensch und Maschine|
QIF aims to deliver capital growth though exposure to the Qatari economy by investing in companies listed on, or soon to be listed on, the Qatar Exchange. 15% of the fund may be invested in companies listed in other GCC countries. QIF is incorporated as a closed-end investment company in the Isle of Man and listed on the main market of the London Stock Exchange.
QRxPharma is an Australian speciality pharmaceutical company principally focused on development of proprietary formulations of morphine and oxycodone. A US launch of lead product MoxDuo IR is expected in the third quarter of FY12, pending approval.
Quadrise Fuels International is the licensor of an oil-in-water emulsion fuel technology enabling refiners to manufacture and market MSAR for use as a low-cost substitute for heavy fuel oil in the marine bunker and power generation sectors.
Quantum Pharmaceuticals is a leading producer and supplier of Special and Special Obtain prescription products for the retail and hospital pharmacy sectors in the UK. It is well placed to capture additional margin through registering a range of existing Specials as licensed products.
Quayle Munro Holdings is an independent investment banking group with three main strands to its business: corporate finance advisory work, specialist fund management and investment on its own account.
QinetiQ provides technical support services to customers in the global aerospace, defence and security markets. The group operates through two divisions: EMEA Services (82% FY16 sales) and Global Products (18%).
QSC AG offers small and mid-size enterprises a range of ICT services from telephony, data transfer, housing and hosting right through to IT outsourcing and consulting. QSC offers its services on the basis of its own next-generation networks (NGN) and operates an open access platform.
Quantum Genomics is a biopharmaceutical company developing QGC001, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment. In-human efficacy data are expected in June 2017.
The Quarto Group is the leading global illustrated book publisher and distribution group.
Quercus Publishing is a trade and contract publisher of physical books and eBooks, with fiction and non-fiction imprints.